Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK.
Goel U, et al. Among authors: dingli d.
Blood Cancer J. 2024 Mar 26;14(1):55. doi: 10.1038/s41408-024-01039-1.
Blood Cancer J. 2024.
PMID: 38531841
Free PMC article.